Organon & Co. (OGN) Stock Analysis
Range Bound setup
Healthcare · Drug Manufacturers - General
Sell if holding. At $13.40, A.R:R is negative (-1.9) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Geographic: outside United States (74.0%); Concentration risk — Product: Established Brands (59.0%).
Organon & Co. sells a portfolio of over 70 prescription products across women's health, biosimilars, and established brands in over 140 countries. The company recorded $6.2 billion in revenues in 2025, with 74% generated outside the United States, through wholesalers, hospitals,... Read more
Sell if holding. At $13.40, A.R:R is negative (-1.9) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Geographic: outside United States (74.0%); Concentration risk — Product: Established Brands (59.0%). Chart setup: RSI 57 mid-range, Bollinger mid-band. Score 5.8/10, moderate confidence.
Passes 7/9 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 49d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
About Organon & Co.
About Organon & Co.
Organon & Co. generated $6.2 billion in revenues in 2025, with approximately 74% ($4.6 billion) from markets outside the United States across more than 140 countries. Established brands — a portfolio of off-patent cardiovascular, respiratory, dermatology, and pain-management products — contributed roughly $3.7 billion (59% of total revenues). Women's health products, including Nexplanon and NuvaRing, added $1.8 billion (28%), while biosimilars accounted for $691 million (11%). In April 2026, the company entered a merger agreement with Sun Pharmaceutical Holdings USA at $14.00 per share.
Organon earns revenue through a portfolio of prescription products sold via drug wholesalers, retailers, hospitals, government agencies, and managed healthcare providers. The established brands segment, while mature, generates 91% of its revenues outside the United States, providing geographic breadth despite generic competition across most brands. Women's health centers on Nexplanon, a long-acting reversible contraceptive implant granted a five-year duration label by the FDA in January 2026, and on Follistim AQ in fertility. Biosimilars are commercialized through agreements with Samsung Bioepis and Henlius, on which Organon depends for ongoing development and supply. Six manufacturing facilities across Belgium, Brazil, Indonesia, Mexico, the Netherlands, and the United Kingdom support production. In 2025, the Audit Committee oversaw an independent internal investigation into Nexplanon sales practices to wholesalers in the United States, identifying material weaknesses in internal controls; in October 2025, the company made a voluntary self-disclosure to the SEC, which subsequently opened an investigation.
Show full overview
Organon faces a regulatory transition with Nexplanon's five-year label extension approved by the FDA in January 2026, which could provide up to three additional years of clinical investigation exclusivity in the United States, though similar applications in the EU and UK remain pending as of 2025. The pending merger with Sun Pharmaceutical Holdings USA, announced April 26, 2026 via Form 8-K at $14.00 per share, represents the most material near-term event for Organon's stakeholders; the company's ongoing SEC investigation and material internal control weaknesses could weigh on integration timelines and regulatory clearance.
See also: Healthcare · Drug Manufacturers - General
From Organon & Co.'s most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated 2026-06-17Recent Developments — Organon & Co.
Latest news
- NEWS Organon's Supplemental Biologics License Application Gets FDA Approval For TOFIDENCE To Treat Chimeric Antigen Receptor — benzinga Jun 10, 2026 positive
- NEWS Deal Dispatch: Sirius XM Mulls Purchase Of iHeartMedia, Uber Buys FlyTaxi, Wren Kitchens Bankruptcy — benzinga May 1, 2026 neutral
- NEWS Organon Q1 Adj. EPS $0.71 Misses $0.83 Estimate, Sales $1.460B Miss $1.484B Estimate — benzinga Apr 30, 2026 negative
- NEWS Organon Stock's Momentum Score Jumps As $11.75 Billion Sun Pharma Takeover Deal Sparks Global Pharma Consolidation Push — benzinga Apr 30, 2026 positive
- NEWS BNP Paribas Downgrades Organon to Neutral, Raises Price Target to $14 — benzinga Apr 29, 2026 negative
Generated 2026-06-17T09:02:27Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHGeographicoutside United States74%10-K Item 1: 'approximately 74% of our 2025 revenues, or $4.6 billion, generated outside the United States'
- HIGHProductEstablished Brands59%10-K Item 1: 'Established Brands... this portfolio contributed approximately $3.7 billion, or approximately 59% of our total revenues'
- LOWSupplierSamsung Bioepis and Henlius10-K Item 1A: 'We rely on our commercialization agreements with Samsung Bioepis, Henlius and Biothera for the successful development and manufacture of our biosimilars products'
Material Events(8-K, last 90d)
- 2026-04-27Item 1.01HIGHOn April 26, 2026, Organon entered an Agreement and Plan of Merger with Sun Pharmaceutical Holdings USA. Each outstanding share converts to $14.00 cash. Company will become a wholly owned subsidiary of Parent at closing.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. At $13.40, A.R:R is negative (-1.9) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Geographic: outside United States (74.0%); Concentration risk — Product: Established Brands (59.0%). Chart setup: RSI 57 mid-range, Bollinger mid-band. Prior stop was $13.32. Score 5.8/10, moderate confidence.
Take-profit target: $13.22 (-1.5% upside). Prior stop was $13.32. Stop-loss: $13.32.
Concentration risk — Geographic: outside United States (74.0%); Concentration risk — Product: Established Brands (59.0%); Analyst target reached - limited upside remaining.
Organon & Co. trades at a P/E of 14.5 (forward 3.7). TrendMatrix value score: 8.0/10. Verdict: Sell.
13 analysts cover OGN with a consensus score of 2.5/5. Average price target: $11.
What does Organon & Co. do?Organon & Co. sells a portfolio of over 70 prescription products across women's health, biosimilars, and established...
Organon & Co. sells a portfolio of over 70 prescription products across women's health, biosimilars, and established brands in over 140 countries. The company recorded $6.2 billion in revenues in 2025, with 74% generated outside the United States, through wholesalers, hospitals, and managed healthcare providers operating six manufacturing facilities.